These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Orphan drug development in the United States. Groft SC CPJ; 1985 May; 118(5):219-22. PubMed ID: 10271306 [TBL] [Abstract][Full Text] [Related]
3. Pediatric testing of prescription drugs: the Food and Drug Administration's carrot and stick for the pharmaceutical industry. Karst KR Am Univ Law Rev; 2000; 49():739-72. PubMed ID: 11067732 [No Abstract] [Full Text] [Related]
4. AIDS drugs in research. Hosp Pharm; 1990 Jun; 25(6):572-3, 576. PubMed ID: 10104831 [No Abstract] [Full Text] [Related]
5. The Orphan Products Board of the Department of Health & Human Services. Crooks GM Prog Clin Biol Res; 1985; 197():19-23. PubMed ID: 4070294 [No Abstract] [Full Text] [Related]
6. Orphan drug development for the treatment of rare chronic diseases. Moore ES Tex Hosp; 1988 Jul; 44(2):20-1. PubMed ID: 10288218 [No Abstract] [Full Text] [Related]
7. Orphan Drug Act on congressional agenda. von Oehsen WH Physician Exec; 1989; 15(3):34-5. PubMed ID: 10313123 [TBL] [Abstract][Full Text] [Related]
8. Problems associated with developing orphan drugs into available therapy. Van Woert MH Prog Clin Biol Res; 1985; 197():171-3. PubMed ID: 4070291 [No Abstract] [Full Text] [Related]
9. View from the Nation's Capital. Romansky MA J Clin Psychopharmacol; 1984 Jun; 4(3):161-2. PubMed ID: 6096408 [No Abstract] [Full Text] [Related]
10. Clinical studies of safety and effectiveness of orphan products; availability of grants; request for applications--FDA. Notice. Fed Regist; 1998 Aug; 63(150):41855-9. PubMed ID: 10181724 [TBL] [Abstract][Full Text] [Related]
11. Clinical studies of safety and effectiveness of orphan products; availability of grants; request for applications. Department of Health and Human Services (HHS), Public Health Service (PHS), Food and Drug Administration (FDA). Notice. Fed Regist; 1999 Jul; 64(141):40012-6. PubMed ID: 10558579 [TBL] [Abstract][Full Text] [Related]
12. The Orphan Drug Act: an engine of innovation? At what cost? Rohde DD Food Drug Law J; 2000; 55(1):125-43. PubMed ID: 12322720 [No Abstract] [Full Text] [Related]
13. Adoption agent. Peota C Minn Med; 2005 Mar; 88(3):8-9. PubMed ID: 15852583 [No Abstract] [Full Text] [Related]
15. Prescription for the Orphan Drug Act: the impact of the FDA's 1992 regulations and the latest congressional proposals for reform. Clissold DB Food Drug Law J; 1995; 50(1):125-47. PubMed ID: 10342989 [No Abstract] [Full Text] [Related]
16. Use of succimer. Marcus SM; Ruck B Clin Pharm; 1992 May; 11(5):387-8; author reply 388-9. PubMed ID: 1316253 [No Abstract] [Full Text] [Related]
17. View from the Nation's Capital. Romansky MA J Clin Psychopharmacol; 1983 Feb; 3(1):47-8. PubMed ID: 6680403 [No Abstract] [Full Text] [Related]
18. The Pharmaceutical Manufacturers Association Commission on Drugs for Rare Diseases. Goldstein GS Prog Clin Biol Res; 1985; 197():35-9. PubMed ID: 4070297 [No Abstract] [Full Text] [Related]
19. When drugs are in short supply. Zurlinden J Nurs Spectr (Wash D C); 1999 Feb; 9(4):15-6. PubMed ID: 10542818 [No Abstract] [Full Text] [Related]